|
GSK and CureVac to develop next generation mRNA COVID-19 vaccines
|
04 February 2021 |
|
Vir Biotechnology and GSK announce NHS-supported AGILE study to evaluate VIR-7832 in the early treatment of COVID-19
|
15 January 2021 |
|
Vir Biotechnology and GSK announce start of NIH-sponsored ACTIV-3 trial evaluating VIR-7831 in hospitalised adults with COVID-19
|
17 December 2020 |
|
Sanofi and GSK announce a delay in their adjuvanted recombinant protein-based COVID-19 vaccine programme to improve immune response in the elderly
|
11 December 2020 |
|
Medicago and GSK announce start of Phase 2/3 clinical trials of adjuvanted COVID-19 vaccine candidate
|
12 November 2020 |
|
Vir Biotechnology and GSK announce global expansion to Phase 3 of COMET-ICE study evaluating VIR-7831 for the treatment of COVID-19
|
07 October 2020 |
|
Sanofi and GSK sign agreements with the Government of Canada to supply up to 72 million doses of adjuvanted COVID-19 vaccine
|
23 September 2020 |
|
Vir Biotechnology and GSK start phase 2/3 study of COVID-19 antibody treatment
|
31 August 2020 |
|
Sanofi and GSK in advanced discussions with European Union to supply up to 300 million doses of COVID-19 vaccine
|
04 August 2020 |
|
GSK and CureVac announce strategic mRNA technology collaboration
|
21 July 2020 |